

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-26. (canceled)

27. (previously presented) A composition of matter in isolated form comprising polysaccharides derivable from Aloe vera with the following characteristics:

- a) the polysaccharides comprise 60-100% D-mannose, 40 - 0 % D-glucose and 0 - 10 % other monosaccharides
- b) the polysaccharides are negatively charged
- c) the polysaccharides bind to a positively charged column.

28. (previously presented) A composition of matter in isolated form according to claim 27 comprising polysaccharides derivable from Aloe vera with the following characteristics:

- a) the polysaccharides comprise 70 - 90 % D-mannose, 30-10% D-glucose and 0-10% other monosaccharides
- b) the polysaccharides are negatively charged
- c) the polysaccharides bind to a positively charged column.

29. (previously presented) A composition of matter according to claim 27 wherein said polysaccharides have an average molecular weight of about 100 - 300 kD.

30. (previously presented) A composition of matter according to claim 27 wherein said polysaccharides comprise D-mannose and D-glucose in a ratio of a range of about 5 to 20.

31. (previously presented) Process to prepare a composition of matter according claim 27 characterized by the following process steps:

a) subfractionation of an Aloe vera extract in two fractions, one with an apparent molecular weight of $> \pm 5$ kD, named subfraction I and one with an apparent molecular weight of $< \pm 5$ kD

b) passing of subfraction I over a positively charged column

c) eluting the part of subfraction I bound to said column with a salt solution, resulting in subfraction I-DI

d) desalting and ultrafiltration of I-DI

e) optionally preparation of subfractions of I-DI with desired apparent molecular weights of > 300 kD, 100 - 300 kD, 50 - 100 kD and 10 - 50 kD.

32. (previously presented) Process according to claim 31 characterized by the application of a pre purification step before process step a over a Sephadex G-25 column to remove materials with affinity for said column.

33. (previously presented) Process according to claim 31 characterized by the application of a DEAE-Sephadex or DEAE-Sepharose column during process step b.

34. (previously presented) Process according to claim 31 characterized by the application of sequential ultra filtration or preparative FPLC over a Superose column.

35. (previously presented) Plant or animal NAG-25 extract comprising a composition of matter as defined in claim 27.

36. (previously presented) Plant NAG-25 extract according to claim 35 with the plant being Aloe.

37. (previously presented) Plant NAG-25 extract according to claim 36 with the Aloe being Aloe vera.

38. (previously presented) Process to prepare a plant or animal NAG-25 extract as defined in claim 35 characterized by

the application of a purification step of a corresponding untreated extract over a Sephadex G-25 column to remove materials with affinity for said column.

39. (previously presented) Aloe ultra filter extract comprising a composition of matter as defined in claim 27.

40. (previously presented) Process to prepare an Aloe ultra filter extract as defined in claim 39 characterized by the application of ultra filtration on the corresponding Aloe extract.

41. (previously presented) A food supplement or dietary foods comprising the composition of matter as defined in claim 27.

42. (previously presented) A cosmetic product comprising the composition of matter as defined in claim 27.

43. (previously presented) A pharmaceutical composition comprising the composition of matter as defined in claim 27.

44. (previously presented) An anti-bacterial, anti-viral or anti-inflammatory pharmaceutical comprising the composition of matter according to claim 41.

45-47. (canceled)

48. (previously presented) Oral dosage form as a tablet, capsule or syrup comprising a composition of matter as defined in claim 27.

49. (previously presented) Topical dosage form as a cream or gel comprising a composition of matter as defined in claim 27.

50. (previously presented) Injectable dosage form as an injection liquid comprising a composition of matter as defined in claim 27.

51. (canceled)